## JAN 2 3 2004 W

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

9		
Application of : Matthias Eckhardt et al U.S. Appln. No. : 10/716,141 Confirmation No. : To be assigned U.S. Filing Date : November 18, 2003 Title of Invention : XANTHINE DERIVATIVE THEIR USE AS PHARMACE Attny. Docket No. : 1/1419		
Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450	·	
January 21, 2004		
TRANSMITTAL LETTER FOR INFORM	ATION DISCL	OSURE STATEMENT
Sir:		
Transmitted herewith concerning the subject appl Statement (Form 1449A/B) under 37 C.F.R. §§1.: hereinbelow.		
1.97(b). This Statement is being filed date of a national application other than a continut §1.53 (d); ii) within three (3) months of the date of 37 C.F.R. §1.491 in an international application; action on the merits; or iv) before the mailing of a request for continued examination under 37 C.F.F.	ned prosecution a of entry of the na iii) before the ma a first Office acti	application under 33 C.F.R. tional stage as set forth in ailing of a first Office
1.97(c). This Statement is being file C.F.R. §1.97(b), but before the mailing date of: i) notice of allowance under 37 C.F.R. §1.311, or iii prosecution in the application. This Statement is	a final action unit) an action that	nder 37 C.F.R. §1.113, ii) a otherwise closes
A statement as specified in 37 C.I	F.R. §1.97(e) [se	e below]; or

The fee set forth in 37 C.F.R. §1.17(p).

	\$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
 §1.97(c) bu	This Statement is being filed after the period specified in 37 C.F.R. t on or before payment of the issue fee. This Statement is accompanied by a s specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
1.97	?(e).
cou	Each item of information contained in the instant information disclosure ement was first cited in any communication from a foreign patent office in a interpart foreign application not more than three (3) months prior to the filing of instant information disclosure statement; or
fore mak info C.F	No item of information contained in the instant information disclosure ement was cited in a communication from a foreign patent office in a counterpart sign application, and, to the knowledge of the person signing this certification after ting reasonable inquiry, no item of information contained in the instant formation disclosure statement was known to any individual designated in 37 and R. §1.56(c) more than three (3) months prior to the filing of the instant formation disclosure statement.
	The fee set forth in 37 C.F.R. §1.17(p).
	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
disclosure s counterpart n section 1	D4(d). Each item of information contained in the accompanying information statement was cited in a communication from a foreign patent office in a application, which communication was not received by any individual designated .56(c) more than thirty (30) days prior to the filing of the accompanying a disclosure statement.

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Susan K. Pocchiari

Attorney for Applicant(s)

Reg. No. 45,016

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877

Tel: (203) 798-5648

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner For Patents P. O. Box 1450 Alexandria, VA 22313-1450

on January 21, 2004.

Susan K. Pocchiari, Reg. No. 45,016

PTO/S8/08a (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10/716,141

Filing Date November 18, 2003

First Named Inventor Matthias Eckhardt et al

Art Unit To be assigned

Examiner Name To be assigned

Attorney Docket Number 1/1419

(Use as many sheets as necessary)

Sheet 1 of 1 Attorney Docket Number 1/1419

	U. S. PATENT DOCUMENTS					
Examiner Cite No.1	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
	Number-Kind Code <sup>2 (f known)</sup>	WIND-00-1111	Applicant of oned bootiment	Figures Appear		
		US-				
		US-				
		US-				
	ļ	US-		TANDON TO THE PROPERTY OF THE		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-		***************************************		
		US-				
		US-				
	***************************************	US-				
		US-				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T€
		WO 02/02560 A2	01/10/2002	Novo Nordisk		
***************************************	ļ	WO 02/068420 A1	09/06/2002	BI Pharma KG	***************************************	
****************	<b>1</b>			***************************************		
***************************************			***************************************			
****************	<b>†</b>			***************************************	,	

	_	
Examiner	 Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at <a href="https://www.tisrito.gov">www.tisrito.gov</a> or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (VVIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.